Esperion Therapeutics’ (ESPR) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a report issued on Tuesday morning,Benzinga reports. They currently have a $16.00 price objective on the biopharmaceutical company’s stock.

ESPR has been the subject of a number of other research reports. JMP Securities reiterated a “market outperform” rating and set a $7.00 target price on shares of Esperion Therapeutics in a research note on Thursday, January 23rd. The Goldman Sachs Group began coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and set a $6.00 price target on shares of Esperion Therapeutics in a research note on Friday, December 13th. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Cantor Fitzgerald started coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $6.75.

Esperion Therapeutics Stock Down 3.8 %

NASDAQ:ESPR opened at $1.79 on Tuesday. The company has a fifty day simple moving average of $2.31 and a two-hundred day simple moving average of $2.12. The company has a market cap of $352.70 million, a price-to-earnings ratio of -2.80 and a beta of 1.01. Esperion Therapeutics has a 52 week low of $1.58 and a 52 week high of $3.94.

Institutional Trading of Esperion Therapeutics

Large investors have recently modified their holdings of the business. Wasatch Advisors LP lifted its stake in shares of Esperion Therapeutics by 38.4% during the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock valued at $38,521,000 after buying an additional 6,483,070 shares during the period. Geode Capital Management LLC raised its stake in Esperion Therapeutics by 4.1% during the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock worth $7,148,000 after purchasing an additional 171,609 shares during the period. State Street Corp raised its stake in Esperion Therapeutics by 2.7% during the third quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock worth $6,360,000 after purchasing an additional 99,802 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Esperion Therapeutics by 1.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,069,117 shares of the biopharmaceutical company’s stock valued at $3,414,000 after acquiring an additional 19,588 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Esperion Therapeutics by 31.0% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 932,008 shares of the biopharmaceutical company’s stock valued at $2,050,000 after acquiring an additional 220,730 shares during the period. 47.39% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.